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ABSTRACT 
 
The first section of this work describes the synthesis of a library of novel rhein analogues that are 
potential anticancer agents. The design of these compounds takes advantage of the ability for 
rhein to intercalate into DNA and as the incorporation of an alkylating agent, which serves to 
covalently modify DNA. In three cell lines, these compounds showed potent cytotoxicity with 
IC50 in the low to mid-µM range. The second project was focused on the development of an 
efficient synthesis of 6H-Isoindolo[2,1-α]indol-6-one (24), a core structure for a number of 
biologically active compounds. The approach is metal-free and uses a Beckmann rearrangement 
followed by an intramolecular cyclization. 
 
 
 
INDEX WORDS:  Anti- cancer agents, Rhein, DNA intercalators, Alkylation, IC50, Beckmann  
   rearrangement 
 
 
 NOVEL RHEIN ANALOGUES AS POTENTIAL ANICANCER AGENTS 
AND  
A NOVEL METAL FREE SYNTHESIS OF 6H-ISOINDOLO[2,1-A]INDOL-6-ONE 
 
 
 
 
 
 
by 
 
 
 
 
 
 
ALEXANDER BORYANOV DRAGANOV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of  
Master of Science 
In the College of Arts and Sciences 
Georgia State University 
2011 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Alexander Boryanov Draganov 
2011 
  
NOVEL RHEIN ANALOGUES AS POTENTIAL ANICANCER AGENTS 
 
 
 
 
 
 
by 
 
 
 
 
ALEXANDER BORYANOV DRAGANOV 
 
 
 
 
Committee Chair:  Binge Wang  
 
Committee:       Maged Henary   
                              Aimin Liu 
 
          
 
 
 
 
 
 
 
 
Electronic Version Approved: 
 
 
 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
May 2011
 iv 
DEDICATION 
To my loving parents Temenuzhka Marinova Draganova and Boryan Asenov Draganov.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
AKNOWLEDGMENTS 
The author is grateful to Dr. Binghe Wang for his support and the opportunity to work on these 
projects. The author also wants to thank Dr. Chaofeng Dai for his guidance throughout the 
projects, Dr. Lifang Wang for her help with the mass spectrometry work, Dr. Guojing Sun and 
Angie D. Calderon who did all of the biological tests described in this work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
TABLE OF CONTENTS 
 
AKNOWLEDGMENTS        v 
 
LIST OF FIGURES         vii 
  
LIST OF SCHEMES         viii 
 
LIST OF TABLES          ix 
 
1  NOVEL RHEIN ANALOGUES AS POTENTIAL    1  
ANTICANCER AGENTS         
 
1.1 Introduction         2 
 
1.2 Results and Discussion       3 
 
1.2.1  Chemical Synthesis        3 
 
1.2.2 Biological Activities        9 
 
1.3 Conclusions         13 
 
1.4 Experimental         14 
 
2     A NOVEL METAL FREE SYNTHESIS OF    24 
      6H-ISOINDOLO[2,1-A]INDOL-6-ONE 
 
2.1   Introduction          25 
 
2.2   Results and Discussion        27 
 
2.3   Conclusions          28 
 
2.4   Experimental          29 
 
References          32 
 
APPENDIX         33 
 
 
 
 
 
 
 
 vii 
LIST OF FIGURES 
 
Figure 1.1. Rhein and other potent anthraquinones.       3 
Figure 1.2. Analogues derived from compound 3 .      5 
          
Figure 1.3. Analogues derived from compound 11 .      6 
              
Figure 1.4. Analogues derived from compound 16 .      7 
Figure 1.5. Analogues derived from compound 20 .      9 
Figure 1.6. Uncommon reagents used       14 
Figure 2.1.Chemical structures of 6H-Isoindolo[2,1-α]indol-6-one    26 
and some biologically relevant analogues. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
LIST OF SCHEMES  
 
Scheme 1.1. Synthetic route to compound 3 .       5 
 
Scheme 1.2. Synthetic route to compound 11 .      6 
 
Scheme 1.3. Synthetic route to compound 16 .      7 
 
Scheme 1.4. Synthetic route to compound 20 .       8 
Scheme 2.1. Synthetic route to the desired 6H-Isoindolo[2,1-α]indol-6-one.  27 
Scheme 2.2. Proposed mechanism for the intramolecular cyclization/   28 
elimination of 31 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
LIST OF TABLES 
Table 1.1. Cytotoxicity of all synthesized compounds      13 
against three different cell lines.         
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
1)  NOVEL RHEIN ANALOGUES AS POTENTIAL ANTICANCER AGENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
1.1) Introduction  
 Rhein is a natural product having an anthraquinone scaffold. It was isolated from the 
ground plant Rhubarb, which belongs to the Rheum family. A number of anthraquinone 
compounds isolated form Rheum such as emodin has been studied and found to have good 
biological activities (Figure 1.1).1 Compounds belonging to the same family of anthraquinones, 
such as doxorubicin and mitoxanthrone, have been on the market as anticancer drugs (Figure 
1.1).1-3 These compounds have shown great anticancer activity; however, they have shown 
serious cardiotoxicity side effects.1,3 Studies have shown that rhein is well tolerated by the 
human body when used as a laxative, and it has anticancer activities against some tumor cells.4-7 
The anticancer activity of rhein against number of cancer cells has been found to be relatively 
low with IC50 in the range of 12~120 µM.4-6,8,9 The potential that the rhein molecule and its 
analogues carry in the anticancer drug discovery, inspired the work that is described in this 
paper.4,7,10 Comparing the rhein core structure to other known anthraquinone anticancer drugs, 
which have already been approved for clinical use (Figure 1.1), brings promise for improvement 
of the anticancer activity by designing new analogues. The compounds mentioned above are 
believed to be non-covalent DNA binding drugs.1,7 In general DNA intercalators have common 
structural features, such as a planar polycyclic aromatic system with different side chains that 
can vary from simple amines to different sugars.5,6,10,11 Intercalators can bind within the minor or 
the major grove of the DNA duplex. Upon binding they may induce conformational changes or 
even rupture of the DNA helix, which can cause cell apoptosis. Another possible mechanism of 
action is the inhibition of enzymes that bind to the DNA, which may disrupt DNA replication, 
transcription, etc. Modification of the planar structure of the molecule is a strategy that can 
 
 
 
 
 
3 
increase the activity of the molecule. Another strategy for improved potency of a compound is by 
varying the side chains. It has been reported that addition of sugars, heterocyclic moieties, and 
amines of different length has improved the activity of some anthraquinones from the Rheum 
family.10,11 Herein we describe the design and synthesis of some novel rhein analogues that have 
alkylators on the side chains at position 3 of the planar polycyclic aromatic system. The idea 
behind the development of these analogues is to use the planar polycyclic aromatic system of 
rhein as an intercalating agent. In addition to the cytotoxycity effects of the intercalating agent on 
carcinoma cells; attachment of an alkylating agent to the rhein core structure is designed to 
interact with nucleophillic species of the DNA and further improve cytotoxicity. We have 
designed analogues that combine two mechanistic strategies for targeting DNA: intercalation and 
covalent DNA modification. 
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Figure 1.1. Rhein and other potent anthraquinones. 
 
 
 
1.2)  Results and Discussion  
 
1.2.1) Chemical Synthesis 
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 Previous studies by Dr. Xiaochuan Yang have shown that attaching an alkylating agent to 
the flat ring system of the rhein core structure at position 3 has the potential for improving the 
cytotoxicity effects of the molecule. A generally accepted mechanism of action of the 
anthraquinone compounds is that they are capable of non-covalent binding to the DNA duplex, 
possibly by intercalation.1,11-14 The combination of a planar polycyclic aromatic system as an 
intercalation moiety and an alkylating agent has been proposed to generate synergy for improved 
cytotoxicity effects.11 Based on Dr. Yang’s observations, a plan was devised to synthesize a 
library of compounds that have an alkylating agents attached to position 3 of the rhein core 
structure with variations in the length and chemical nature of the linker. Two main approaches 
were considered when building this series of analogues. The first approach involves the direct 
replacement of the carboxylic acid group at position 3 of the core structure with an amino group. 
The second approach in creating novel rhein analogues involves the use of commercially 
available rhein (1) and the attachment of amine linkers of various sizes and chemical properties 
to position 3 of the polycyclic aromatic system before the addition of alkylating agents. Two 
different sized linkers were chosen to be attached to the Rhein (1) compound: a four-carbon 
diamine linker and a long diamine with ethylene glycol moieties for improved solubility. 
The synthesis of the first series of compounds started with rhein (1). The first step 
involved the formation of acyl azide at position 3. The formation of the azide was done by 
addition of diphenylphosphoryl azide (DPPA) to (1) in anhydrous dimethylformamide (DMF). 
Triethyl amine (TEA) was used in the reaction as a base, and the yield of the reaction was 40%. 
The second step of the synthesis used Curtis rearrangement through heating at reflux in 1,4-
dioxane for 2 hours and then hydrolysis with NaOH solution, giving a reaction yield of 30%. The 
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synthesized compound 3  was used as a starting material for three analogues, each containing 
different alkylating agent (Scheme 1.1). The amine at position 3 of compound 3  was acylated 
using three agents, leading to three different compounds. Chloroacetyl chloride was used to form 
compound 5 , bromoacetyl bromide was used to result in compound 6 , and iodoacetyl chloride 
was used for the formation of compound 7  (Figure 1.3).  
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Reagents and conditions: i) DPPA, Et3N, DMF, 30 min., room temperature ii) dioxane, NaOH, reflux, 4 h, 31 % 
yield. 
 
Scheme 1.1. Synthetic route to compound 3. 
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Figure 1.2. Analogues derived from compound 3. 
 
A similar approach was used to synthesize three more rhein analogues using amine (11) as a 
stating material (Scheme 1.2). Compound 11  was acylated using chloroacetyl chloride, 
bromoacetyl bromide, and iodoacetyl chloride, to give compounds 12 , 13 , and 14  respectively 
(Figure 1.3). The reaction yields were in the range between 30-40 %. The low yields for these 
reactions are due to the extremely poor solubility of the anthraquinone compounds being 
synthesized. The starting material 1  itself has poor solubility in dichloromethane (DCM). 
 
 
 
 
 
6 
Increased amount of the alkylating agent, up to two equivalent, to the free amine did not improve 
the reaction yields. Addition of one equivalent of TEA did not affect the reaction outcome as 
well. In an attempt to improve the yields the temperature of the reaction mixture was increased to 
600 C; no significant increase in yield was observed. 
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Scheme 1.2. Synthetic route to compound 11. 
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Figure 1.3. Analogues derived from compound 11. 
 
  The same approach was used for the synthesis of the rhein-amine compounds 17  and 18  
(Figure 1.4). The carboxylic group attached at the 3 position of compound 1 was converted to an 
activated ester by using N-hydroxysuccinimide (NHS) and coupling reagent 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDCI). Without further purification, by reacting the 
product with N-(3-minopropyl)carbamic acid tert-butyl ester (34) (Figure 1.6), the desired Boc-
 
 
 
 
 
7 
protected amine 15  was synthesized in quantitative yield (Scheme 1.3). The next step in the 
formation of compounds 17 , and 18  was the de-protection of the Boc protecting group. The de-
protection was carried out by stirring the protected amine in trifluoroacetic acid (TFA). Once the 
free amine 16  was obtained it was reacted with chloroacetyl chloride and bromoacetyl N-
hydroxy succinimide to give compounds 17  and 18  in 36% and 32% yield respectively.  
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Reagents and conditions: i)NHS, EDCI, DCM, 00C to room temperature, overnight ii) 34, Et3N, DCM, room 
temperature, 2 h.  iii) TFA, DCM, room temperature 2 h, quantitative yield. 
 
Scheme 1.3. Synthetic route to compound 16.  
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Figure 1.4. Analogues derived from compound 16. 
 
In an attempt to improve solubility, a long chain linker containing the ethylene glycol moiety 
was used in the synthesis of three more rhein analogues. N-[(tert-Butoxycarbonyl]-4,7,10-trioxa-
1,13-tridecanediamine (35) (Figure 1.6) was directly added to the activated ester 4 generated in 
situ from 1  using EDCI and NHS to give the Boc- protected amine 19  in 98% yield (Scheme 
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1.4). This was followed by the de-protection of the Boc-group in TFA, giving the free amine 20  
in quantitative yield. Amine 20  was reacted with chloroacetyl chloride, bromoacetyl N-hydroxy 
succinimide, and iodoacetyl chloride to give analogues 21 , 22 , and 23  respectively (Figure 1.5). 
Despite the addition of liker 35  containing the ethylene glycol moiety, the solubility of the 
synthesized compounds did not improve and the yields ranged from 30% to 39%. All of the 
eleven compounds were examined for their in vitro cytotoxicity using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-- diphenyltetrazolium bromide) assay.15 The results are reported and 
discussed in the next section of this paper.   
 
O
O
OHOH
O
H
N O
O
O
H
N
O
O
OHOH
OH
O
1
O
O
OHOH
O
O
N
O
O
i ii
Boc
O
O
OHOH
O
H
N O
O
O NH2
iii
19
20
4
 
Reagents and conditions i)NHS, EDCI, DCM, 00C to room temperature, overnight ii) 35, Et3N, DCM, room 
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Scheme 1.4. Synthetic route to compound 20. 
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Figure 1.5. Analogues derived from compound 20. 
 
 
1.2.2) Biological Activities 
 The in vitro cytotoxicity studies of the synthesized compounds were performed in three 
different cell lines (HeLa, Hek, and KB). The activities of the herein described analogues were 
compared to that of rhein itself and doxorubicin. Doxorubicin is a marketed anticancer drug 
derived from anthraquinones from the Rheum family as well (Figure 1.1).1 The quantitative 
evaluation of the cytotoxicity screenings for the synthesized compounds was done by performing 
MTT assay. The measurement of survival or proliferation of mammalian cells is a key factor in 
determining the effects of novel drug compounds. MTT assay is used to measure the viability of 
the cells. It is a colorimetric assay that utilizes a yellow tetrazolium dye. This dye is converted 
into a deeply colored product in live cells and is easy to be quantified. In this method, the yellow 
colored MTT is converted to purple colored formazan product. By dissolving in a solvent such as 
DMSO or isopropanol, formazan gives a “blue” colored product. The absorbance of this colored 
solution is quantified and analyzed by using a spectrophotometer at wavelengths generally 
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between 500 nm and 600 nm. The conversion of tetrazolium dye to the formazan product occurs 
in the presence of mitochondrial dehydrogenase enzyme. The mitochondrial dehydrogenase is 
produced only in active and viable cells. Thus the conversion can be directly related to the 
number of viable cells and inversely related to the cytotoxicity of the compounds tested. Due to 
the poor solubility of the compounds, all of the solutions used for biological testing were 
prepared by using DMSO as solvent. The cytotoxicity studies against HeLa cell line reveal that 
the compounds’ activities are in the µM range and vary from IC50 = 40 µM to IC50 = 1.3 µM 
(Table 1.1). The least potent rhein analogue (6) (IC50 = 40 µM) is 2.5 times more potent that 
rhein itself (IC50 = 100 µM). The most potent compound 12 (IC50 = 1.3 µM) is about 100-fold 
more potent than rhein (IC50 = 100 µM) against the cervical cancer cell HeLa. Compound 12  
(IC50 = 1.3 µM) appears to have similar cytotoxicity against HeLa when compared with 
doxorubicin (IC50 = 1.4 µM). All of the synthesized compounds showed significant improvement 
of the activity compared to rhein (Table 1.1). After analyzing the results obtained by the 
cytotoxicity assay against Hek cell lines, an observation can be made that all of the rhein 
analogues showed dramatically improved activity with IC50 values in the single digit µM range 
(Table 1.1). However, all of the analogues showed activity that is ten times lower than 
doxorubicin (IC50 = 0.14 µM) (Table 1.1). The most potent compound against Hek cells is 
compound 18  (IC50 = 1.4 µM), and the least potent are compounds 6  and 17  (IC50 = 8 µM) 
(Table 1.1). The described rhein analogues have been tested against a third cell line, KB. Once 
again all of the synthesized compounds showed great improvement in their activity compared to 
rhein. However, the most potent compound against this cell line, 18 (IC50 = 4.8 µM),  showed 
activity that is ten times lower than that of doxorubicin (IC50 = 0.4 µM). The least potent 
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compound 13  (IC50 = 38 µM) against the KB cells showed two and a half times increase in 
activity compared to rhein (IC50 = 1100 µM). On the other hand it showed one hundred fold 
lower activity compared to doxorubicin (IC50 = 0.4 µM) (Table 1.1). From the analysis of the 
data obtained from the cytotoxicity assays one can see that there are four compounds that carry 
great potential against the studied carcinoma cells. Rhein analogues 5 , 12 , 14 , and 18  showed 
low micro molar IC50 values against all three cell lines assayed (Table 1.1). Two of the 
compounds that posses the highest activities 12  and 14 , have the two hydroxyl groups on the 
anthraquinone moiety protected using a methoxy group. The fact that the above-mentioned 
compounds have the lowest IC50 values implies that the methoxy protection at positions 1 and 8 
on the anthraquinone moiety plays a crucial role in the increased activity of these compounds. 
On the other hand, it has been reported that rhein analogues having the methoxy groups at 
positions 1 and 8 do not show any cytotoxicity against L1210 leukemic cells, which suggest that 
there might be other structural factors that might result in the increased cytotoxicity.11 
Considering the fact that in previous studies the methoxy protected compounds did not show 
cytotoxic activity against carcinoma cells one can speculate that in fact the key factor for the 
improved activity is the addition of alkylating agent to position 3 of the polycyclic aromatic 
system. The intercalating power of the 1, 8-methoxy protected compounds might not be as good 
as the one of the free 1, 8-hydroxy compounds, but one can assume that interactions of the planar 
part of these molecules with the the DNA base pairs can bring the alkylator in close proximity to 
the highly nuclephillic DNA backbone. Having the alkylating agent in close proximity to the 
DNA backbone or a nucleophilllic group of neighboring base can promote covalent interactions. 
Intercalation as well as covalent interactions with the DNA can cause conformational changes 
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and even rupture of the DNA helix, which can induce apoptosis. Two more important structural 
factors can play an important role; the type of alkylator and the length of the linker. In the case of 
12  and 14,  the alkylating agent is directly attached to the amine at position 3. Compounds 12  
and 14  have shown great improvement in cytotoxycity compared to rhein. These compounds can 
be used as leads for future development because they carry the potential for further improvement 
of their activity. The use of a longer linker between the polycyclic aromatic system and the 
alkylating agent might have positive effects on the compounds’ cytotoxicities. One can notice 
that other three compounds that have a short linker at position 3 did not show high potency. On 
the contrary, some of them, 6 , 7 , and 13 , have the highest IC50 values in the in vitro studies 
(Table 1.1). The type of leaving group on the alkylating agent could play an important role in 
increasing the activity of the compounds. Initially a hypothesis was made based on the atomic 
size and the chemical properties of the leaving groups of the alkylating agents; compounds 
containing iodide and bromide should have exhibited better activity than compounds containing 
chloride. Strong evidence supporting that hypothesis was not obtained from the performed 
studies. Two of the four most potent compounds contain chlorides as leaving groups after a 
potential alkylation reaction. One of them has iodide, and one has bromide. Clearly the most 
potent compound against all of the three cell lines studies is compound 12  that carries the 
combination of methoxy protected hydroxy groups and a chloride as leaving group after potential 
alkylation reaction. This compound can be used as a starting point for further development of a 
successful DNA intercalating agent. Clearly the attempt to increase solubility by the addition of a 
long linker containing ethylene glycol did not result in the expected increase of the biological 
activity that can be significant enough for further development. A potentially good method for 
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structurally developing compound 12  in the pursuit of increased biological activity is the use of 
computational software that can help in explaining the intercalation mechanism of this 
compound and the ideal positioning of the alkylating moiety. Knowing the way of action of 
compound 12  and the way it interacts with its target can greatly help in the design of more 
potent DNA intercalators.    
 
Table 1.1. Cytotoxicity of all synthesized compounds against three different cell lines. 
Compounds IC50 (µM) against HeLa IC50 (µM) against Hek IC50 (µM) against KB 
Rhein >100 >100 >100 
5 4 4 4.5 
6 40 8 15 
7 10 2 9 
12 1.3 1.9 5.2 
13 8 2.3 38 
14 2.5 1.4 10 
17 16 8 19 
18 3 1.4 4.8 
21 14 8 21 
22 7 2.2 9 
23 5.8 4 8 
Doxorubicin 1.5 0.15 0.4 
 
 
1.3) Conclusions 
 
 In conclusion, eleven new rhein analogues have been synthesized by linking an alkylating 
agent to position 3 of the core structure. In addition, attempts were made to place three different 
alkylating agents. The synthesized analogues were tested in vitro by using the MTT assay against 
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three different cell lines: HeLa, Hek, and KB. All of the compounds tested showed improved 
cytotoxicity compared to rhein with IC50 values in the µM range against cancer cells. Four of the 
compounds 5 , 12 , 14 , and 18 , showed significant improvement, one of them stands out with an 
impressive IC50 value of 1.3 µM against HeLa cells. The improvement of cytotoxycity at such 
leves is evidence that the combination between an intercalating moiety and an alkylating agent 
can be a successful strategy for designing DNA targeting anticancer drugs. 
 
1.4) Experimental Section 
 
 Rhein (1) was purchased from Nanjing ZeLang Medical Technology Co. LTD, China, 
and directly used without further purification. Other starting materials and solvents were 
purchased from Aldrich and Acros. Some starting materials such as 11  and the Boc- protected 
amine of compounds 15 , and 35  were obtained from past synthesis done by other group member 
working on the same project. 1H spectra were obtained on a Bruker 400 NMR spectrometer in a 
deuterated solvent with TMS (δ = 0.00 ppm).  For all reactions, analytical grade solvents were 
used. Anhydrous solvents were used for all moisture-sensitive reactions. 
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Figure 1.6. Uncommon reagents used. 
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1,8-Dihydroxy-3-amino-anthraquinone (3) .  
Compound 1  (500 mg, 1.7 mmol) was suspended in anhydrous DMF (6 mL) in a dry round 
bottom flask and cooled to 0 oC. TEA (490 µL, 3.5 mmol) was added at 0 oC. DPPA (400 µL, 1.8 
mmol) was added drop wise after 1  was completely dissolved. The reaction mixture was stirred 
at room temperature for 20 minutes. TLC (hexanes: ethyl acetate = 3:1) showed complete 
consumption of the starting material. The solvent was evaporated in vacuo and the obtained oil 
was purified by silica gel column chromatography using a mixture of hexanes and ethyl acetate 
in a 2:1 ratio as the eluent. 200 mg brown- yellow powder were obtained. Compound 2  was 
dissolved in 1,4- dioxane (4 mL) and stirred under reflux for 2 hours. After the color of the 
solution turned from brown to bright red and TLC (hexanes: ethyl acetate = 2:1) showed product 
formation, the 1,2-dioxane volume was reduced by half using a rotavapor. 2N NaOH (4 mL) was 
added to the solution and a fine precipitate formed. The suspension was stirred under reflux for 2 
additional hours. The solution was cooled and neutralized by addition of 1N HCl. The precipitate 
was too fine to be filtered so it was extracted by using DCM (3 × 10 mL) and washed with water 
(2 × 5 mL) and brine (1 × 5 mL). The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo.  The obtained residue is bright red powder that was purified using silica 
gel column chromatography, with mixture of eluent hexanes and ethyl acetate in 10:1 ratio (50 
mg, 31% yield). 1H NMR (acetone - d6): δ 12.04 (s, 1H), 12.27 (s, 1H), 7.67 (d, 1H, J = 1.2 Hz), 
7.56- 7.50 (m, 2H), 7.27- 7.23 (m, 1H), 7.14-(d, 1H, J = 2.0 Hz), 6.37 (d, 1H, J = 2.0 Hz); MS: 
m/z [M-H]- calculated C14H9NO4 254.01, found 254.04. 
 1,8-Dihydroxy-3-(2’-chloro-acetamido)-anthraquinone (5) .  
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Chloroacetyl chloride (23 µL, 0.3 mmol) was injected slowly into the solution of (3) (50 mg, 0.2 
mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 2 h. 
The reaction mixture was followed by TLC (DCM: MeOH = 10:1) and diluted by H2O (20 mL) 
and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers were combined, 
dried over MgSO4, filtered and concentrated in vacuo.. The residue was purified with silica gel 
column chromatography eluting with DCM: MeOH (60:1) to give an orange colored solid 
product (20 mg, 30% yield). 1H NMR (DMSO - d6): δ 12.02 (s, 1H), 11.06 (s, 1H), 7.87 (s, 1H), 
7.809- 7.79 (m, 2H), 7.74- 7.72 (m, 1H), 7.33- 7.31 (m, 1H), 4.36 (d, 2H, J = 1.2 Hz); MS: m/z 
[M-H]- calculated C16H10ClNO5 330.00, found 330.10. 
1,8-Dihydroxy-3-(2’-bromo-acetamido)-anthraquinone (6) .  
Bromoacetyl bromide (26 µL, 0.3 mmol) was injected slowly into the solution of (3) (50 mg, 0.2 
mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 2 h. 
The reaction mixture was followed by TLC (DCM: MeOH = 10:1) and diluted by H2O (20 mL) 
and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers were combined, 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified with silica gel 
column chromatography. The product was eluted with DCM: ethyl acetate (20:1). Orange color 
solid was obtained as product (18 mg, 30 % yield). 1H NMR (DMSO - d6): δ 12.05 (s, 1H), 10.18 
(s, 1H), 7.88 (d, 1H, J = 2.0 Hz), 7.82- 7.80 (m, 2H), 7.78-7.76 (m, 1H), 7.35 (d, 1H, J = 8.4 Hz), 
4.14 (s, 2H); MS: m/z [M-H]- calculated C16H10BrNO5 392.9, found 392.1. 
1,8-Dihydroxy-3-(2’-iodo-acetamido)-anthraquinone (7) .  
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Iodoacetyl chloride (27 µL, 0.3 mmol) was injected slowly into the solution of (3) (50 mg, 0.2 
mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 2 h. 
The reaction was followed by TLC (DCM: MeOH = 10:1), and after completion was diluted by 
H2O (20 mL) and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
with silica gel column chromatography. The compound was eluted with DCM: MeOH (1:0, 
60:1). Orange color solid was obtained as product (24 mg, 33% yield). 1H NMR (DMSO - d6): δ 
11.96 (s, 1H), 11.85 (s, 1H), 7.80 (d, 1H, J = 2.1 Hz), 7.75 (d, 1H, J = 2.0 Hz), 7.60-7.58 (m, 
2H), 7.38 (d, 1H, J = 8.4 Hz), 3.87 (s, 2H); MS: m/z [M-H]+ calculated C16H10INO5 422.9, found 
422.1. 
1,8-Methoxy-3-(2’-chloro-acetamido)-anthraquinone (12) .  
Chloroacetyl chloride (21µL, 0.2 mmol) was injected slowly into the solution of (11) (50 mg, 
0.17 mmol) in anhydrous 1,4-dioxane (5 mL). The mixture was stirred at room temperature for 2 
h. The reaction was followed by TLC (DCM: MeOH = 10:1), and after completion was diluted 
by H2O (20 mL) and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
with silica gel column chromatography. It was eluted with DCM: MeOH (60:1). Orange color 
solid was obtained as product (8 mg, 30% yield). 1H NMR (DMSO – d6): δ 10.81 (s, 1H), 7.93 
(d, 1H, J = 2.0 Hz), 7.82 (d, 1H, J = 2.0 Hz), 7.76- 7.682 (m, 2H), 7.55-7.529 (m, 1H), 4.34 (s, 
2H), 3.93 (d, 6H, J = 7.6 Hz); MS: m/z [M+H]+ calculated C18H14ClNO5 360.0, found 360.2. 
1,8-Methoxy-3-(2’-bromo-acetamido)-anthraquinone (13) .  
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Bromoacetyl bromide (23 µL, 0.26 mmol) was injected slowly into the solution of (11) (50 mg, 
0.17 mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 2 
h. The reaction was followed by TLC (DCM: MeOH = 10:1), and after completion was diluted 
by H2O (20 mL) and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
with silica gel column chromatography. The compound was eluted with DCM: MeOH (1:0, 
60:1). Orange color solid was obtained as product (13 mg 20% yield). 1H NMR (DMSO - d6): δ 
10.95 (s, 1H), 7.91 (d, 1H, J = 2.0 Hz), 7.82 (d, 1H, J = 2.0 Hz), 7.76- 7.68 (m, 2H), 7.55-7.53 
(m, 1H), 4.10 (s, 2H), 3.95 (d, 6H, J = 7.2 Hz); MS: m/z [M+H]+ calculated C18H14BrNO5 405.2, 
found 405.2. 
1,8-Methoxy-3-(2’-iodo-acetamido)-anthraquinone (14) .  
Iodoacetyl chloride (24 µL, 0.26 mmol) was injected slowly into the solution of (11) (50 mg, 
0.17 mmol) in anhydrous 1,4-dioxane (5 mL). The mixture was stirred at room temperature for 2 
h. The reaction was followed by TLC (DCM: MeOH = 10:1), and after completion was diluted 
by H2O (20 mL) and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
with silica gel column chromatography. The residue was eluted with DCM: MeOH (1:0: 60:1). 
Orange color solid was obtained as product (27 mg, 35% yield). 1H NMR (DMSO - d6): δ 7.92 
(d, 1H, J = 2.0 Hz), 7.78 (d, 1H, J = 2.0 Hz), 7.76- 7.66 (m, 2H), 7.48-7.46 (m, 1H), 3.93 (d, 6H, 
J = 5.2 Hz), 3.87 (s, 2H); MS: m/z [M+H]+ calculated C18H14INO5 451.9, found 452.0.  
1,8-Dihydroxy-3-(2’-amido-7’-amino)-anthraquinone (16) .  
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The Boc- protected amine of (15) (200 mg, 0.4 mmol) was suspended in DCM (5 mL). 
Trifluoroacetic acid was added  (5 mL) and the solution was stirred at room temperature and 
followed by TLC (DCM: MeOH = 10:1), until full de- protection was achieved. The organic 
layer was concentrated in vacuo. The residue was purified with silica gel column 
chromatography. The residue was eluted with DCM: MeOH (10:1, 8:1, 1:1). Orange color solid 
was obtained as product (142 mg, quantitative yield). 1H NMR (DMSO - d6): δ 8.96 (t, 1H, J = 
5.6 Hz), 8.14 (d, 1H, J = 1.6 Hz), 7.81- 7.74 (m, 1H), 7.73-7.71 (m, 2H), 7.40- 7.38 (m, 1H), 
3.38 (d, 2H, J = 5.6 Hz), 2.80 (s, 2H), 2.45 (s, 2), 1.57 (s, 4H);  
1,8-Dihydroxy-3-(9’-chloro-aceta-2’,7’diamido)-anthraquinone (17) .  
Chloroacetyl chloride (24 µL, 0.21 mmol) was injected slowly into the solution of 16  (50 mg, 
0.14 mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 2 
h. The reaction was followed by TLC (DCM: MeOH = 10:1), and after completion was diluted 
by H2O (20 mL) and the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
with silica gel column chromatography. The residue was eluted with DCM: methanol (60:1). 
Orange color solid was obtained as product (22 mg, 36% yield). 1H NMR (DMSO - d6): δ 11.92 
(s, 2H), 8.23 (s, 1H), 7.86- 7.84 9(m, 1H), 7.77 (d, 2H, J = 8.4 Hz), 7.43 (d, 1H, J = 8.4 Hz), 4.03 
(s, 2H), 3.24- 3.20 (m, 2H), 3.25- 3.18 (m, 1H), 1.54- 1.50 (m, 2H), 1.49- 1.45 (m, 2H); MS: m/z 
[M+H]+ calculated C21H19ClN2O6 431.1, found 431.2. 
1,8-Dihydroxy-3-(9’-bromo-aceta-2’,7’diamido)-anthraquinone (18) .  
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A solution of bromoacetyl N-hydroxy succinimide (39.4 mg, 0.17 mmol) in 1 mL of anhydrous 
1,4- dioxane was injected slowly into the solution of 16  (50 mg, 0.14 mmol) in anhydrous 
dioxane (5 mL). The mixture was stirred at room temperature for 2 hours. The reaction was 
followed by TLC (DCM: MeOH = 10:1), and after completion was diluted by H2O (20 mL) and 
the suspension was extracted with CH2Cl2 (2 × 50 mL). The organic layers were combined, dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified with silica gel column 
chromatography. The compound was eluted with DCM: methanol (60:1). Orange color solid was 
obtained as product (21mg, 32% yield). 1H NMR (DMSO - d6): δ 11.9 (s, 2H), 8.91 (t, 1H, J = 
5.6 Hz), 8.24 (t, 1H, J = 5.6 Hz), 8.16 (d, 1H, J = 1.6 Hz), 7.84- 7.80 (m, 1H), 7.76-7.63 (m, 2H), 
7.41- 7.35 (m, 1H), 4.0 (s, 1H), 3.15- 3.10 (m, 2H), 2.52 (m, 2H), 1.51- 1.43 (m, 4H); MS 
[M+H]+ calculated C21H19BrN2O6 475.04, found 475.1 
1,8-Dihydroxy-3-(6’,9’,12’-trioxa-2’,16’-tridecanediamino)-anthraquinone (20) .  
Rhein (1) (500 mg, 1.8 mmol) was dissolved in dry DCM and cooled to 0 o C. NHS (202 mg, 1.9 
mmol) was added and the reaction mixture was stirred for 5 minutes followed by addition of 
EDCI (278 mg, 1.8 mmol). The reaction was monitored by TLC (DCM: MeOH = 8:1) and 
stirred for 4 hours. To the reaction mixture, 35 (624 mg, 1.9 mmol) was added followed by TEA 
(183 µL, 1.3 mmol) and the mixture was stirred overnight at room temperature. After TLC 
showed consumption of the starting material, the organic solvent was concentrated in vacuo. The 
residue was purified using silica gel column chromatography with an eluent consisting of 
mixture between DCM: MeOH = 10:1. 940 mg brown oil was obtained. The Boc- protected 
amine 19  (500 mg, 0.9 mmol) was suspended in DCM (7 mL). TFA (7 mL) was added and the 
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solution was stirred at room temperature overnight. The reaction was followed by TLC (DCM: 
MeOH = 8:1). The organic layer was concentrated in vacuo. The residue was purified with silica 
gel column chromatography. The residue was eluted with DCM: MeOH (10:1, 8:1, 1:1). Orange 
color solid was obtained as product (438 mg, quantitative yield). 1H NMR (DMSO - d6): δ 7.9(s, 
1H), 7.66- 7.60 (m, 2H), 7.54 (s, 1H), 7.28 (d, 1H, J = 8.0 Hz), 3.61-3.52 (m, 13H), 3.43 (t, 2H, J 
= 6.4 Hz), 3.22 (s, 2H), 3.08 (t, 2H, J = 6.3 Hz), 1.91- 1.84 (m, 4H);  
1,8-Dihydroxy-3-(18’-chloro-aceta-6’,9’,12’-trioxa-2’,16’-tridecanediamido)-
anthraquinone (21) .  
Chloroacetyl chloride (24 µL, 0.3 mmol) was injected slowly into the solution of 20  (90 mg, 0.2 
mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 30 
minutes. The reaction was followed by TLC (DCM: MeOH = 10:1). The organic layer was 
concentrated in vacuo . The residue was purified using silica gel column chromatography. The 
compound was eluted with DCM: methanol (60:1). Orange color solid was obtained as product 
(11 mg, 30% yield). 1H NMR (DMSO - d6): δ 8.23 (s, 1H), 7.86- 7.81 (m, 1H), 7.79-7.73 (m, 
2H), 7.45- 7.41 (m, 1H), 4.01 (s, 2H), 3.42- 3.51 (m, 14H), 3.40 (t, 2H, J = 6.0 Hz), 3.15- 3.10 
(m, 2H), 1.73 (t, 2H, J = 6.2 Hz), 1.67 (t, 2H, J = 6.2 Hz); MS: m/z [M-H]+ calculated 
C27H31ClN2O9 563.1, found 563.3. 
1,8-Dihydroxy-3-(18’-bromo-aceta-6’,9’,12’-trioxa-2’,16’-tridecanediamido)-
anthraquinone (22) .  
Bromoacetyl N-hydroxy succinimide (79 mg, 0.3 mmol) was injected slowly into the solution of 
(20) (80 mg, 0.2 mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room 
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temperature for 1 hour. The reaction was followed by TLC (DCM: MeOH = 10:1), and 0.5 
equivalent of TEA was added. The reaction was diluted by H2O (2 mL) and the suspension was 
extracted with CH2Cl2 (2 × 20 mL). The organic layers were combined, dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified using silica gel column 
chromatography. The compound was eluted with DCM: methanol (1:0, 60:1). Orange color solid 
was obtained as product (47 mg, 39% yield). 1H NMR (DMSO - d6): δ 11.90 (s, 2H), 8.18 (s, 
1H), 7.83 (t, 1H, J = 8.4 Hz), 7.61-7.45 (m, 2H), 7.42- 7.40 (m, 1H), 4.02 (s, 2H), 3.52- 3.45 (m, 
14H), 3.39 (t, 2H, J = 6.2 Hz), 3.17- 3.08 (m, 2H), 1.82- 1.75 (m, 2H), 1.67- 1.61 (m, 2H); MS: 
m/z [M-H]- calculated C27H31BrN2O9 607.1, found 606.3. 
1,8-Dihydroxy-3-(18’-iodo-aceta-6’,9’,12’-trioxa-2’,16’-tridecanediamido)-
anthraquinone (23) .  
Iodoacetyl chloride (25 µL, 0.3 mmol) was injected slowly into the solution of 20  (90 mg, 0.2 
mmol) in anhydrous 1,4- dioxane (5 mL). The mixture was stirred at room temperature for 1 
hour. The reaction was followed by TLC (DCM: MeOH = 10:1). The organic layer was 
concentrated in vacuo. The residue was purified using silica gel column chromatography. The 
product was eluted with DCM: methanol (60:1). Orange color solid was obtained as product (26 
mg, 20% yield). 1H NMR (DMSO - d6): δ 8.12 (d, 1H, J = 1.6), 7.79- 7.73 (m, 2H), 7.68-7.67 
(m, 1H), 7.33- 7.31 (m, 1H), 3.68- 3.60 (m, 11H), 3.57- 3.47 (m, 7H), 3.36- 3.31 (m, 1H,), 3.26- 
3.21 (m, 1H), 1.94- 1.88 (m, 2H), 1.80- 1.71 (m, 2H); MS: m/z [M-H]+ calculated C27H31IN2O9 
655.1, found 655.3. 
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MTT assay.  HeLa, Hek, and KB cell lines were purchased from ATCC. All of the cell lines 
were cultured in RPMI-1640 medium. The medium was supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin. For the cytotoxicity assays, cells were seeded into 96-
well plate (2.5 × 104 in 100 µL per well for HeLa, 3.0 × 104 for KB, and 5 × 104 for Hek). The 
compounds were dissolved or suspended in DMSO to make 10 mM stock solutions. The stock 
solution was diluted using DMSO to various concentrations. 1µL of each concentration was 
diluted 100 fold with medium into the well plate keeping the DMSO < 1% throughout the 
experiment. Addition of compounds was performed after adherent cells reached 40-50% 
confluence. After incubation for 48 h. at 37 oC in humidified atmosphere with 5% CO2, 10 µL of 
MTT (5 mg/mL in PBS) was added. After addition of MTT the cells were incubated for another 
4 h. The culture medium was then aspirated and 100 µL of DMSO was added to each well. The 
96-well plate was read by microarray reader for optical density at 490 nm. All tests were 
performed in triplicates and IC50 values were estimated from the averaged response curves.  For 
compounds with IC50 < 100 µM, the MTT assay was repeated. 
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2) A NOVEL METAL FREE SYNTHESIS OF 6H-ISOINDOLO[2,1-α]INDOLO-6-ONE 
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2.1)  Introduction 
 
6H-Isoindolo[2,1-α]indol-6-one (24) is a core structure for a number biologically active 
compounds.16-19 Indole-based structures derived from heterocyclic systems resembling 6H-
isoindolo[2,1-α]indol-6-one (24) have been used as melatonin MT3 ligands 2617 and potential 
anti-tumor agents 25  18,20 as well as intermediate 27  in the synthesis of bacterial NorA efflux 
pump inhibitors 16,19 (Figure 2.1). Melatonin is an indole derived neurohormone synthesized in 
the pineal gland in all mammalians.17,21 Two melatonin receptors MT1 and MT2 are known and 
have been widely studied in the human body.17,21 However, a third MT3 receptor has been found, 
that needs to be closely studied.21 It has been reporter that isoindolo compounds that have a core 
structure resembling compound 24  bind to this receptor and give the opportunity for further 
binding studies of the MT3 receptor.17 The importance of these isoindolo compounds to the study 
of the melatonin MT3 receptor brings the need for a short and efficient synthetic route towards 
their core synthesis. Another important area of application in which isoindolo compounds have 
found place is the design of anticancer drugs. Targeting DNA, synthesizing intercalating agents, 
and developing topoisomerase II poisons is strategy that carries great potential in the anticancer 
drug design process. A number of compounds resembling the structure of 6H-isoindolo[2,1-
α]indol-6-one (24) has shown great potential and cytotoxicity against some carcinoma cells in 
the low micromolar concentrations.18,20 Being able to apply a short and efficient synthetic route 
to the synthesis of the core structure will bring ease to the development of libraries of potential 
anticancer agents. A convenient synthetic route to isoindolo compounds carrying similar 
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structures as compound 24  can also be applied for the development of bacterial NorA efflux 
pump inhibitors. It has been reported that compound 24  is an intermediate in the synthetic rout 
towards number of Nor A efflux inhibitors.16 The here in described route is not just time efficient 
but also cost efficient. Route consisting of reactions with relatively cheap commercially available 
starting material and giving high yields can greatly contribute to the development of more novel 
Nor A efflux pump inhibitors. A number of routes for the synthesis of 6H-isoindolo[2,1-α]indol-
6-one (24) and its analogues have been reported. 22-32 
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Figure 2.1.Chemical structures of 6H-Isoindolo[2,1-α]indol-6-one and some biologically relevant analogues.  
 
To our best knowledge, most of the strategies described in the literature involve the use of 
indole-based compounds as the starting materials and expensive metal catalysts.18,20 We herein 
report an efficient method that does not rely on an indole starting material and costly metal 
catalysts 
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2.2) Results and Discussion 
  
The synthesis began with a relatively cheap, commercially available starting material 
dibenzocyclohepten-5-one (28). Through reaction with hydroxylamine, oxime 29  was formed in 
93% yield following standard procedures using dry pyridine as the solvent (Scheme 2.1). 33   
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Scheme 2.1. Synthetic route to the desired 6H-Isoindolo[2,1-α]indol-6-one; Reagents and conditions: i) NH2OH-
HCl, Pyridine, reflux, 20 h., 93 % yield, ii) TFA, DCM, reflux, overnight, 95 % yield, iii) Br2, DCM, room 
temperature, 3 h., 67 % yield, iv) TEA, THF, room temperature, overnight, 70 % yield.  
 
 
The true challenge of this route was to establish the Beckmann rearrangement reaction 
conditions that would provide a convenient purification method due to the extremely poor 
solubility of lactam 30 . The standard Beckmann rearrangement conditions, heating the oxime in 
polyphosphoric acid, yielded a black solid that was insoluble in number of organic solvents 
including acetone, methanol, ethyl acetate, and hexanes, and had poor solubility in DMF and 
DMSO as well.33 As a solution, we discovered that the Beckmann rearrangement could be 
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achieved by refluxing the oxime intermediate 29  in TFA, which led to the desired lactam 30  in 
95% yield.34 The work up procedure consisted of simple evaporation of the TFA followed by 
silica gel column chromatography. Subsequent bromination through addition of molecular 
bromine to a suspension of lactam 30  in DCM led to 9,10-dibromodibenzo[b,f]azocin-6-one 
(31) in 67% yield. 35 The last step involves intramolecular cyclization under basic conditions and 
elimination of hydrogen bromide (Scheme 2.2). This was accomplished by dissolving compound 
31  in THF followed by the slow addition of an excess amount of a base. A number of bases were 
studied to optimize this intramolecular cyclization/elimination reaction: t-BuOK, LDA, 
KHMDS, and TEA. The base that gave the best yields was TEA (70% yield). The yields for the 
reactions using other bases ranged from 0 – 47%. 
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Scheme 2.2. Proposed mechanism for the intramolecular cyclization/elimination of 31 
 
 
2.3) Conclusions 
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We have developed a new four-step synthetic route (Scheme 2.1) to isoindolo[2,1-α]indol-6-
one (24). The overall yield of the route is 42 %. The described route is efficient and metal free, 
and allowed for the de novo construction of the indole and isoindole rings that are important in 
the synthesis of number biologically relevant compounds.   
 
2.4) Experimental Section 
 
Dibenzocyclohepten-5-one (24) was purchased form TCI America, and directly used without 
further purification. Other compounds and solvents were purchased from Acros and Aldrich. 
Analytical grade solvents were used for all reactions. 1H and 13C NMR spectra were recorded on 
a Bruker 400 NMR spectrometer in a deuterated solvent with TMS (δ = 0.00 ppm) or the NMR 
solvent as the internal reference. The deuterated solvents for NMR were purchased from 
Cambridge Isotope Laboratories, Inc. Mass spectra were recorded on an API 3200 LC/MS/MS 
system. 
 
Dibenzocyclohepten-5-one oxime (29): 
A mixture of dibenzocyclohepten-5-one (28) (2.0 g, 9.65 mmol), hydroxylamine 
hydrochloride (1.0 g, 14.47 mmol), and dry pyridine (12 mL) was heated under reflux for 20 hrs. 
The pyridine in the reaction mixture was removed through evaporation in vacuum and the 
residue was poured into hexanes followed by acidification with 1 M hydrochloric acid. The two 
layers were placed in an ice bath for 2 hrs, which lead to precipitation. The solid was filtered and 
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re-crystallized in hexanes to give a white powder product (1.9 g, 93 % yield). The compound 
was characterized by 1H NMR and MS.33  
 
 
Dibenzo[b,f]azocin-6-one (30): 
A round-bottom flask was charged with dibenzocyclohepten-5-one oxime (29) (100 mg, 0.45 
mmol) and TFA (5 mL). The reaction mixture was heated under reflux overnight.. The TFA was 
evaporated and the resulting product was purified via silica gel column chromatography, using a 
mixture of hexanes and ethyl acetate in a 4:1 ratio to give a grey powder product (92 mg, 95% 
yield). The compound was characterized by 1H NMR and MS.33 
 
9, 10-Dibromodibenzo[b,f]azocin-6-one (31): 
Dibenzo[b,f]azocin-6-one (7) (100 mg, 0.45 mmol) was suspended in dry DCM (3 mL) and 
cooled to 0 oC. Br2 (8.6 µL, 0.167 mmol) was slowly added in and the reaction mixture was 
stirred for 3 hrs at room temperature. Reaction was quenched with the addition of saturated 
sodium sulfite aqueous solution (1 mL). The organic and the aqueous layers were separated and 
the aqueous solution was extracted using DCM (3 × 5 mL). The combined organic layers was 
washed with brine, dried over MgSO4, filtered and concentrated in vaccuo. The product was 
eluted from silica gel column chromatography with a solvent consisting of hexanes and ethyl 
acetate in a 6:1 ratio to give a light-brown powder product (116 mg, 67% yield). At this point the 
product consists of a mixture of stereoisomers, and was used in the next step without further 
purification. 1H NMR (DMSO–d6): δ 10.28 (s, 1H), 7.75 - 7.69 (m, 1H), 7.68 - 7.41 (m, 1H), 
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7.40 – 7.02 (m, 5H), 5.98 – 5.81(m, 2H). MS (ESI); m/z calculated C15H11Br2NO [M+H]+: 
382.06; found: 381.90.  
 
 
Isoindolo[2,1-a]indolo-6–one (24): 
9,10-Dibromodibenzo[b,f]azocin-6-one (31) (50 mg, 0.131 mmol) was dissolved in dry THF 
(5 mL). TEA (2.7 mL) was slowly added to the reaction mixture. After stirring at room 
temperature overnight, water (10 mL) was added and the organic layer was separated. The 
aqueous solution was extracted using DCM (3 × 10 mL). The combined organic layer was 
washed with brine, dried over MgSO4, filtered and concentrated in vaccuo. The residue was 
purified by silica gel column chromatography with an eluent consisting of hexanes and ethyl 
acetate in a 5:1 ratio to give a bright yellow-green solid (20 mg, 70 % yield). 1H NMR (CDCl3): 
δ 7.82 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.44- 7.40 (m, 2 H), 7.37 (d, J = 7.6 Hz, 1H), 
7.26-7.18 (m, 2 H), 7.09 (m, 1H), 6.65 (s, 1 H); 13C NMR (CDCl3): δ 162.6, 138.9, 134.7, 134.5, 
133.9, 133.7, 133.5, 128.8, 126.3, 125.3, 123.9, 122.3, 121.3, 113.6, 103.5. MS (ESI); m/z 
calculated C15H9NO [M+ H]+: 219.07; found 219.7. 
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APPENDIX 
The contents of this appendix consist of NMR and MS spectra of the compounds which synthesis 
is described above.   
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Rhein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
 
1,8-Dihydroxy-3-amino-anthraquinone (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100%MeOH+0.5%NH4OH+10%HCOOH 15:42:12  05-Apr-2011
m/z
240 250 260 270 280 290 300 310 320 330 340 350
%
0
100
ABD_LFS_POS_WANG_040511 246 (4.582) Cm (235:251) TOF MS ES+ 
9.07e3255.2
244.3
338.5
315.4
285.2268.2 300.2
 37 
1,8-Dihydroxy-3-(2’-chloro-acetamido)-anthraquinone (5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100%MeOH+0.5%NH4OH 16:14:48  05-Apr-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ABD_III_7_NEG_WANG_040511 6 (0.112) Cm (5:9) TOF MS ES- 
8.81e3330.1
233.2
438.1
366.1
391.3 474.1
100%MeOH+0.5%NH4OH 16:14:48  05-Apr-2011
m/z
328 329 330 331 332 333 334 335 336
%
0
100
ABD_III_7_NEG_WANG_040511 6 (0.112) Cm (5:9) TOF MS ES- 
8.81e3330.1
332.1
331.1
333.1
 39 
1,8-Dihydroxy-3-(2’-bromo-acetamido)-anthraquinone (6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100%MeOH+0.5%NH4OH 15:57:20  05-Apr-2011
m/z
372 374 376 378 380 382 384 386 388 390 392 394 396 398 400 402
%
0
100
ABD_III_9_NEG_WANG_040511 52 (0.969) Cm (52:77) TOF MS ES- 
1.94e4392.1
376.0374.0
394.1
393.1 395.1
100%MeOH+0.5%NH4OH 15:57:20  05-Apr-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ABD_III_9_NEG_WANG_040511 52 (0.969) Cm (52:77) TOF MS ES- 
7.28e4420.1
312.1
233.2
209.1 285.2
392.1
500.1
923.2815.2
 41 
1,8-Dihydroxy-3-(2’-iodo-acetamido)-anthraquinone (7) 
 
 
 
 
 
 
 
 
100%MeOH+0.5%NH4OH, Leuink as ITSD 16:58:27  05-Apr-2011
m/z
420 430 440 450 460 470 480 490 500 510 520 530 540 550 560
%
0
100
ABD_III_11_HRMS_WANG_040511 222 (4.128) AM (Cen,4, 80.00, Ar,5000.0,554.26,0.70); Sm (SG, 2x3.00); Cm (215:229)
1.94e4421.9533
439.9638
549.8638
529.9554
457.9344
518.0168470.0081 498.9552483.0523
*;554.2615
100%MeOH+0.5%NH4OH 16:52:37  05-Apr-2011
m/z
415 416 417 418 419 420 421 422 423 424 425 426 427 428
%
0
100
ABD_III_11_WANG_040511 123 (2.283) Cm (123:135) TOF MS ES- 
3.11e3420.2
422.1
421.2
423.1
 42 
 
 43 
 
1,8-Methoxy-3-(2’-chloro-acetamido)-anthraquinone (12). 
 
 
 
   
50%ACN+0.1%TFA 18:23:16  30-Mar-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ALEXANDER_ABD_III_143_WANG_POS 43 (0.800) Cm (42:47) TOF MS ES+ 
9.54e3360.2
154.1
243.1
405.2
603.1 671.3
50%ACN+0.1%TFA 18:23:16  30-Mar-2011
m/z
358 359 360 361 362 363 364 365 366 367 368 369
%
0
100
ALEXANDER_ABD_III_143_WANG_POS 47 (0.874) TOF MS ES+ 
1.88e3360.2
362.2
361.2
363.2 364.2
 44 
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1,8-Methoxy-3-(2’-bromo-acetamido)-anthraquinone (13) 
 
 
 
 
 
 
 
 
 
 
 
 
50%ACN+0.1%TFA 18:51:07  29-Mar-2011
m/z
350 360 370 380 390 400 410 420 430
%
0
100
ALEXANDER_ABD_III_145_WANG_POS 56 (1.043) Cm (45:59) TOF MS ES+ 
8.74e3392.2
362.1
358.2 373.1
405.2
421.2
 46 
 
 47 
1,8-Methoxy-3-(2’-iodo-acetamido)-anthraquinone (14) 
 
 
 
 
50%ACN+0.1%TFA, leuink as ITSD 18:41:14  29-Mar-2011
m/z
400 420 440 460 480 500 520 540 560
%
0
100
ALEXANDER_ABD_III_147_HRMS_WANG_POS_01 141 (2.616) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 2x3.00)
1.86e3451.9995
421.0536
*
556.2771
518.0422
493.3222
473.9647 537.3312
50%ACN+0.1%TFA, leuink as ITSD 18:41:14  29-Mar-2011
m/z
451 452 453 454 455 456
%
0
100
ALEXANDER_ABD_III_147_HRMS_WANG_POS_01 141 (2.616) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Sm (SG, 2x3.00)
1.86e3451.9995
451.1567
452.9994
454.0077 455.1718 456.1944
 48 
 
 49 
1,8-Dihydroxy-3-(18’-iodo-aceta-6’,9’,12’-trioxa-2’,16’-tridecanediamido)-anthraquinone (23). 
 
 
 
 
 
50%ACN+0.1%TFA 18:11:20  29-Mar-2011
m/z
652 653 654 655 656 657 658 659 660 661 662
%
0
100
ALEXANDER_ABD_III_45_WANG_POS 115 (2.137) Cm (106:119) TOF MS ES+ 
1.29e3655.3
652.6 653.6 654.6
656.3
659.4657.3 661.3660.4
50%ACN+0.1%TFA 18:11:20  29-Mar-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ALEXANDER_ABD_III_45_WANG_POS 115 (2.137) Cm (106:119) TOF MS ES+ 
8.35e3
321.1
169.2
563.3
362.2
449.4 655.3 781.3
 50 
 
 51 
 
1,8-Dihydroxy-3-(18’-bromo-aceta-6’,9’,12’-trioxa-2’,16’-tridecanediamido)-anthraquinone (22). 
 
 
 
 
50%ACN+0.1%TFA 18:00:59  29-Mar-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ALEXANDER_ABD_III_43_WANG_POS_01 158 (2.945) Cm (146:158) TOF MS ES+ 
3.13e4563.3
321.1
169.2
283.2203.2 405.2
50%ACN+0.1%TFA 18:00:59  29-Mar-2011
m/z
604 605 606 607 608 609 610 611 612 613 614 615
%
0
100
ALEXANDER_ABD_III_43_WANG_POS_01 158 (2.945) Cm (146:158) TOF MS ES+ 
2.04e3607.3
605.4
604.3 606.3
609.3
608.3 610.3
611.5 613.5612.5 615.5614.5
 52 
 
 53 
1,8-Dihydroxy-3-(18’-chloro-aceta-6’,9’,12’-trioxa-2’,16’-tridecanediamido)-anthraquinone (21). 
 
 
 
 
 
100%MeOH+0.1%HCOOH 17:44:24  29-Mar-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ALEXANDER_ABD_III_41_WANG_POS 66 (1.231) Cm (66:79) TOF MS ES+ 
6.28e3
283.2
154.1
196.1
359.3
315.3
563.3391.3
449.4
634.6 722.7 810.7
100%MeOH+0.1%HCOOH 17:44:24  29-Mar-2011
m/z
561 562 563 564 565 566 567 568 569
%
0
100
ALEXANDER_ABD_III_41_WANG_POS 66 (1.231) Cm (66:79) TOF MS ES+ 
1.14e3563.3
560.6
562.5561.6
565.3564.3
566.3 567.5
568.5
 54 
 
 55 
1,8-Dihydroxy-3-(9’-chloro-aceta-2’,7’diamido)-anthraquinone (17). 
 
 
 
 
 
50%ACN+0.1%TFA 18:22:47  29-Mar-2011
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
ALEXANDER_ABD_III_35_WANG_POS 40 (0.745) Cm (34:42) TOF MS ES+ 
9.28e3431.2
321.1
283.2
169.2
359.3
861.5563.3 667.3
50%ACN+0.1%TFA 18:22:47  29-Mar-2011
m/z
426 428 430 432 434 436 438 440
%
0
100
ALEXANDER_ABD_III_35_WANG_POS 40 (0.745) Cm (34:42) TOF MS ES+ 
9.28e3431.2
433.2
432.2
434.2
 56 
 
 57 
1,8-Dihydroxy-3-(9’-bromo-aceta-2’,7’diamido)-anthraquinone (17). 
 
 
100%MeOH+0.5%NH4OH 18:51:48  29-Nov-2010
m/z
100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000
%
0
100
ALEX_ABD_III_39_WANG_ESI_NEG_112910 81 (1.508) Cm (60:83) TOF MS ES- 
8.26e4429.0
465.0
 58 
 
 
 
100%MeOH+0.5%NH4OH 18:51:48  29-Nov-2010
m/z
471 472 473 474 475 476 477 478 479
%
0
100
ALEX_ABD_III_39_WANG_ESI_NEG_112910 81 (1.508) Cm (60:83) TOF MS ES- 
4.53e3475.0
473.0
474.0
476.0
477.0
 59 
 
